Ripretinib Inhibits HIV-1 Transcription Through Modulation of PI3K-AKT-mTOR

Researchers performed a high-throughput screening of FDA-approved compound library in the J-Lat A2 cell line to discover more efficacious latency-promoting agents. They discovered ripretinib being an LPA candidate, which was validated and observed to hinder proviral activation in cell models harboring latent infections, as well as CD4+ T cells derived from infected patients.